CD3D
ENSG00000167286
Target class
Unclassified protein
Chromosome
11
Approved drugs
10
Clinical candidates (approved and in development)
15
- Approved drugs
- 10
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- No
- Target name
- CD3D
- Gene name
- CD3 delta subunit of T-cell receptor complex
- Gene symbol
- CD3D
- Previous gene symbols
- T3D
- Protein name
- T-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d)
- CD3DELTA
- CD3-DELTA
- Gene biotype
- Protein coding
- Gene family
- CD molecules
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 27
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 51.36
- Tissue specificity (Gini)
- 0.747
- Tissue specificity (tau)
- 0.947
- KEGG gene identifiers
- hsa:915
- Protein interaction confidence
- 0.839865
- Protein interaction partners
- 52
- R-HSA-198933
- R-HSA-202424
- R-HSA-202427
- R-HSA-202430
- R-HSA-202433
- R-HSA-389948
- R-HSA-8856825
- R-HSA-8856828
- End position
- 118342705
- Start position
- 118334537
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein.
- Tissue specificity (tau)
- 0.947434
- Expression inequality (Gini)
- 0.747315
Expression in transcripts per million
- Spleen
- 51.36
- Whole Blood
- 30.03
- Small Intestine - Terminal Ileum
- 27.79
- Lung
- 11.85
- Colon - Transverse
- 5.44
Expression in transcripts per million
- Spleen51.36
- Whole Blood30.03
- Small Intestine - Terminal Ileum27.79
- Lung11.85
- Colon - Transverse5.44
- Bladder5.07
- Vagina4.26
- Fallopian Tube4.18
- Stomach4.12
- Adipose - Visceral (Omentum)3.77
- Cervix - Endocervix3.53
- Thyroid3.52
- Prostate3.44
- Esophagus - Mucosa3.1
- Minor Salivary Gland2.7
- Adipose - Subcutaneous2.34
- Artery - Coronary2.13
- Breast - Mammary Tissue2.1
- Cervix - Ectocervix1.79
- Uterus1.78
- Skin - Not Sun Exposed (Suprapubic)1.76
- Artery - Aorta1.72
- Nerve - Tibial1.62
- Brain - Spinal cord (cervical c-1)1.25
- Skin - Sun Exposed (Lower leg)1.2
And 29 more, listed on the interactive page.
- GO:0007166
- GO:0050852
- GO:0005886
- GO:0030669
- GO:0042101
- GO:0042105
- GO:0004888
- GO:0005515
- GO:0032395
- GO:0042802
Related records
Trials (624)
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Compassionate Use (CU) Program of Odronextamab
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Drugs (15)
- Blinatumomab T cell surface glycoprotein CD3 cross-linking agent
- Catumaxomab T cell surface glycoprotein CD3 cross-linking agent
- Elranatamab T cell surface glycoprotein CD3 binding agent
- Epcoritamab T cell surface glycoprotein CD3 binding agent
- FBT-A05 T cell surface glycoprotein CD3 cross-linking agent
- Flotetuzumab T cell surface glycoprotein CD3 binding agent
- Foralumab T cell surface glycoprotein CD3 inhibitor
- Glofitamab T cell surface glycoprotein CD3 binding agent
- Mosunetuzumab T cell surface glycoprotein CD3 binding agent
- Muromonab-CD3 T cell surface glycoprotein CD3 inhibitor
- Odronextamab T cell surface glycoprotein CD3 binding agent
- Solitomab T cell surface glycoprotein CD3 cross-linking agent
- Talquetamab T cell surface glycoprotein CD3 binding agent
- Tarlatamab T cell surface glycoprotein CD3 binding agent
- Teclistamab T cell surface glycoprotein CD3 binding agent